RESUMO
More people are using electronic cigarettes (e-cigarettes) and fewer people are smoking conventional tobacco cigarettes. A wide variety of e-cigarettes are available and there is emerging evidence that they may help with smoking cessation. This evidence-based clinical review summarises the latest evidence regarding use of e-cigarettes as smoking cessation aids. The ongoing debate surrounding the safety and regulation of e-cigarettes is also discussed.
Assuntos
Sistemas Eletrônicos de Liberação de Nicotina , Agentes de Cessação do Hábito de Fumar/uso terapêutico , Abandono do Hábito de Fumar/métodos , Vaping/efeitos adversos , União Europeia , Humanos , Nicotina/farmacologia , Agentes de Cessação do Hábito de Fumar/efeitos adversos , Reino Unido , Vaping/legislação & jurisprudênciaRESUMO
The objective was to evaluate the resource use and cost of hospitalisation for febrile neutropenia (FN) from the health-payer's perspective. This was a single centre study. Adults undergoing chemotherapy, who were admitted for FN, were identified prospectively. Patient medical records were reviewed retrospectively. Demographics and resource utilisation data were obtained from a cohort of 32 patients (69% female, mean age = 58.8 years). Twenty-five per cent of patients had more than one FN episode. In total, 42 FN episodes were captured; 60% of episodes had occurred within the first two cycles of chemotherapy. The bootstrap estimation was used to determine mean hospital length of stay (LOS) with standard deviation (±SD) and mean costs ± SD. The mean LOS was 7.3 ± 0.5 days. The mean cost per FN episode was 8915 ± 718. The major cost driver was hospital bed-stay (mean cost of 6851 ± 549). Other cost drivers included antibacterial treatment at 760 ± 156, laboratory investigations at 538 ± 47 and the requirement for blood bank products at 525 ± 189. To our knowledge, this is the first investigation of the cost of chemotherapy induced FN within the context of the Irish healthcare setting.
Assuntos
Antineoplásicos/efeitos adversos , Neutropenia Febril Induzida por Quimioterapia/economia , Atenção à Saúde/economia , Custos de Cuidados de Saúde/estatística & dados numéricos , Tempo de Internação/economia , Neoplasias/tratamento farmacológico , Idoso , Antibacterianos/economia , Antibacterianos/uso terapêutico , Antineoplásicos/uso terapêutico , Transfusão de Componentes Sanguíneos/economia , Neutropenia Febril Induzida por Quimioterapia/tratamento farmacológico , Neutropenia Febril Induzida por Quimioterapia/epidemiologia , Estudos de Coortes , Análise Custo-Benefício , Feminino , Humanos , Irlanda/epidemiologia , Masculino , Pessoa de Meia-Idade , Neoplasias/economia , Neoplasias/epidemiologia , Estudos Prospectivos , Estudos RetrospectivosRESUMO
BACKGROUND AND PURPOSE: Intracranial haemorrhage in neurosarcoidosis (NS-ICH) is rare, poorly understood and the diagnosis of NS may not be immediately apparent. METHODS: The clinical features of three new NS-ICH cases are described including new neuropathological findings and collated with cases from a systematic literature review. CASES: (i) A 41-year-old man with headaches, hypoandrogenism and encephalopathy developed a cerebellar haemorrhage. He had neuropathological confirmation of NS with biopsy-proven angiocentric granulomata and venous disruption. He responded to immunosuppressive therapy. (ii) A 41-year-old man with no history of hypertension was found unconscious. A subsequently fatal pontine haemorrhage was diagnosed. Liver biopsy revealed sarcoid granulomas. (iii) A 36-year-old man with raised intracranial pressure headaches presented with a seizure and a frontal haemorrhage. Hilar lymph node biopsy confirmed sarcoidosis, and he was treated successfully. Systematic review: Twelve other published cases were identified and collated with our cases. Average age was 36 years and M:F = 2.3:1; 46% presented with neurological symptoms and 31% had CNS-isolated disease. Immediate symptoms of ICH were acute/worsening headache or seizures (60%). ICH was supratentorial (62%), infratentorial (31%) or subarachnoid (7%). Forty percent had definite NS, 53% probable NS and 7% possible NS (Zajicek criteria). Antigranulomatous/immunosuppressive therapy regimens varied and 31% died. CONCLUSIONS: This series expands our knowledge of the pathology of NS-ICH, which may be of arterial or venous origin. One-third have isolated NS. Clinicians should consider NS in young-onset ICH because early aggressive antigranulomatous therapy may improve outcome.
Assuntos
Doenças do Sistema Nervoso Central/complicações , Hemorragias Intracranianas/diagnóstico , Hemorragias Intracranianas/etiologia , Sarcoidose/complicações , Adulto , Humanos , Imageamento por Ressonância Magnética , Masculino , Tomografia Computadorizada por Raios XAssuntos
Neoplasias do Mediastino/diagnóstico , Complicações Neoplásicas na Gravidez/diagnóstico , Timoma/diagnóstico , Adulto , Feminino , Humanos , Neoplasias do Mediastino/tratamento farmacológico , Placenta Prévia/diagnóstico , Gravidez , Complicações Neoplásicas na Gravidez/tratamento farmacológico , Timoma/tratamento farmacológicoRESUMO
A curious association of three rare tumours was described by Carney in 1977. 'Carney's triad' characteristically includes multifocal pulmonary chondroma, gastric stromal sarcoma and extra-adrenal paraganglioma. Patients may exhibit complete or incomplete expression of the triad. Carney acknowledged that, of 79 patients, only 17 possessed all three tumours. We report here two patients with incomplete expression of Carney's triad.
Assuntos
Condroma/diagnóstico , Tumores do Estroma Gastrointestinal/diagnóstico , Neoplasias Hepáticas/diagnóstico , Neoplasias Pulmonares/diagnóstico , Paraganglioma Extrassuprarrenal/diagnóstico , Adulto , Antibacterianos/uso terapêutico , Antineoplásicos/uso terapêutico , Benzamidas , Broncopatias/tratamento farmacológico , Broncopatias/etiologia , Feminino , Humanos , Mesilato de Imatinib , Neoplasias Primárias Múltiplas/diagnóstico , Piperazinas/uso terapêutico , Pirimidinas/uso terapêutico , Tomografia Computadorizada por Raios XAssuntos
Broncoscopia , Pneumopatias/diagnóstico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Biópsia , Criança , Feminino , Fluoroscopia , Humanos , Pneumopatias/terapia , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos TestesRESUMO
Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition of uncertain aetiology that should be considered in the differential diagnosis of patients who experience breathlessness, cough and reduced exercise tolerance. IPF is characterized histologically by the presence of usual interstitial pneumonia, and often has typical radiological appearances. Long-term successful management options are limited and frequently unsuccessful; as the disease progresses, palliation of symptoms becomes the mainstay of treatment. In a minority of patients, lung transplantation provides the only hope of long-term survival. The median survival of patients with IPF is approximately 3 years, which in turn emphasizes the need for further investigation into its pathogenesis and potential disease-modifying pharmacological therapies.
Assuntos
Fibrose Pulmonar , Doença Aguda , Anticoagulantes/uso terapêutico , Antifibrinolíticos/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Sequestradores de Radicais Livres/uso terapêutico , Humanos , Transplante de Pulmão , Prognóstico , Inibidores de Proteínas Quinases/uso terapêutico , Fibrose Pulmonar/diagnóstico , Fibrose Pulmonar/terapiaRESUMO
Although asthma is one of the most common chronic respiratory conditions, it often remains unrecognized and undertreated, while patients are often reluctant to comply with regular inhaled anti-inflammatory and bronchodilator therapy. Allergic rhinitis co-exists with asthma in as many as 40% of patients, and can be regarded as a continuum of the same inflammatory disease process. Corticosteroids are the 'gold standard' first-line treatment for both conditions, and have a significant impact upon underlying inflammation, symptoms and long-term outcome. Cysteinyl leukotrienes are potent airway inflammatory mediators, suggesting that treatment antagonizing their effects could play a role in disease management. In recent years, leukotriene receptor antagonists have provided a further therapeutic option in the management of allergic airways disease. These drugs are orally active, can be administered once daily, and provide a systemic approach to the management of patients with asthma and allergic rhinitis. We review the pharmacology of leukotriene receptor antagonists, their potential role in clinical practice in patients with allergic airways disease, and likely areas for further research.
Assuntos
Antiasmáticos/uso terapêutico , Antagonistas de Leucotrienos/uso terapêutico , Hipersensibilidade Respiratória/tratamento farmacológico , Agonistas Adrenérgicos beta/uso terapêutico , Asma/tratamento farmacológico , Quimioterapia Combinada , Glucocorticoides/uso terapêutico , Humanos , Proteínas de Membrana/fisiologia , Receptores de Leucotrienos/fisiologia , Rinite/tratamento farmacológicoRESUMO
BACKGROUND: Eosinophils and their secreted mediators are heavily implicated as effector cells in asthma and other allergic diseases. Comparisons were made between expression of CD45, CD45RA, CD45RB and CD45RO by eosinophils from asthmatic patients and non-asthmatic atopic and non-atopic, non-asthmatic control subjects. METHODS: Twenty-seven patients with asthma and 33 control subjects were recruited for the study. Eosinophil expression of CD45, CD45RA, CD45RB and CD45RO was established by immunostaining and flow cytometry was performed on whole leucocyte samples. Eosinophil apoptosis in response to CD45 and CD45 isoform monoclonal antibody (mAb)-dependent receptor ligation was assessed by binding of annexin V and flow cytometry. RESULTS: Eosinophils from patients with asthma expressed significantly (P<0.05) higher levels of pan-CD45 and CD45RO compared with eosinophils from non-asthmatic, non-atopic subjects. No significant correlations were found between expression of either pan-CD45 or CD45RO and the degree of symptoms in the asthmatic patients as defined by lung function (FEV1 and FEF25-75) and methacholine PD20. Increased expression of pan-CD45 or CD45RO did not appear to be a consequence of the atopic phenotype. Higher expression of pan-CD45 or CD45RO by eosinophils from asthmatic patients was not associated with greater sensitivity to CD45 and CD45RO mAb receptor ligation-induced eosinophil apoptosis. CONCLUSION: Higher expression of CD45 and CD45RO by eosinophils from asthmatic patients appeared to be a consequence of asthma rather than atopy and further supports a role for activated eosinophils in asthma.
Assuntos
Asma/metabolismo , Eosinófilos/metabolismo , Antígenos Comuns de Leucócito/metabolismo , Adolescente , Adulto , Asma/patologia , Asma/fisiopatologia , Feminino , Citometria de Fluxo , Fluxo Expiratório Forçado , Volume Expiratório Forçado/fisiologia , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-IdadeAssuntos
Instituição de Longa Permanência para Idosos/estatística & dados numéricos , Casas de Saúde/estatística & dados numéricos , Admissão do Paciente/estatística & dados numéricos , Papel do Médico , Médicos de Família/psicologia , Doença Aguda , Idoso , Humanos , Inquéritos e Questionários , Fatores de TempoRESUMO
BACKGROUND: Allergic rhinitis and asthma commonly coexist and are both mediated by similar inflammatory mechanisms. Leukotriene antagonists may therefore be an alternative to corticosteroid therapy. OBJECTIVE: To compare oral montelukast with inhaled plus intranasal budesonide in patients with seasonal allergic rhinitis and asthma. PATIENTS AND METHODS: A single-blind double-dummy placebo-controlled crossover study was performed comparing once daily 10 mg oral montelukast with 400 microg inhaled plus 200 microg intranasal budesonide in 12 patients with allergic rhinitis and asthma: mean (S.E.) age 34.0 years (2.7), forced expiratory volume in 1 s (FEV1) 91.2 (3.8)% predicted. Each treatment was for 2 weeks with a 1-week placebo run-in and washout. Measurements were made after each active treatment and placebo for: adenosine monophosphate bronchial challenge, exhaled and nasal nitric oxide. Patients also recorded their domiciliary peak expiratory flow, nasal peak inspiratory flow, asthma and seasonal allergic rhinitis symptoms. RESULTS: There were no significant differences between the placebos for any measurement. For adenosine monophosphate PC20, geometric mean fold differences (95% confidence interval (CI) for difference) were 6.4 (2.2-18.6) for placebo vs. budesonide, 2.9 (1.0-8.4) for placebo vs. montelukast, and 2.1 (1.1-4.5) for budesonide vs. montelukast. For exhaled nitric oxide (p.p.b.) there was significant (P < 0.05) suppression with both montelukast (10.9) and budesonide (10.1) compared with placebo (18.8). For nasal nitric oxide and nasal peak flow there were only significant differences with budesonide compared with placebo. Both treatments reduced total seasonal allergic rhinitis symptoms but only budesonide had a significant effect on nasal symptoms. CONCLUSION: Once-daily inhaled plus intranasal budesonide and once daily montelukast showed comparable efficacy on lower airway, but only the budesonide had significant efficacy on upper airway inflammatory markers. Both treatments significantly reduced allergic rhinitis symptoms.
Assuntos
Antiasmáticos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Asma/tratamento farmacológico , Rinite Alérgica Sazonal/tratamento farmacológico , Acetatos/administração & dosagem , Acetatos/uso terapêutico , Administração Oral , Administração Tópica , Adulto , Biomarcadores , Budesonida/administração & dosagem , Budesonida/uso terapêutico , Intervalos de Confiança , Estudos Cross-Over , Ciclopropanos , Humanos , Quinolinas/administração & dosagem , Quinolinas/uso terapêutico , Método Simples-Cego , SulfetosRESUMO
OBJECTIVE: To assess the addition of a leukotriene receptor antagonist and a long-acting beta(2)-agonist as second-line therapy in asthma. DESIGN: Placebo-controlled, double-dummy, crossover study. SETTING: Outpatient clinic. PATIENTS: Twenty patients with persistent asthma not controlled with inhaled corticosteroid therapy. INTERVENTIONS: Montelukast 10 mg once daily, or salmeterol, 50 microg bid, each for 2 weeks with 1-week run-in and washout placebo periods. MEASUREMENTS AND RESULTS: Adenosine monophosphate (AMP) bronchial challenge, blood eosinophil count (EOS), exhaled nitric oxide, and lung function after both placebo periods and after the first and last doses of each active treatment. Patients recorded their domiciliary peak expiratory flow (PEF), asthma symptoms, and rescue bronchodilator requirement (RES) twice daily throughout the study. For the primary end point of the provocative concentration of AMP causing a 20% fall in FEV(1), compared to placebo (47.5 +/- 13.0 mg/mL), there were significant differences with the first (114.1 +/- 36.9 mg/mL) and last (94.2 +/- 30.4 mg/mL) doses of montelukast as well as the first (160.1 +/- 64.5 mg/mL) but not the last (70.1 +/- 23.7 mg/mL) dose of salmeterol. Only montelukast produced significant suppression of the EOS. Neither drug affected exhaled nitric oxide levels. There were significant improvements with the first doses of salmeterol for all parameters of lung function. After 2 weeks of treatment, there were significant improvements with both drugs for RES and morning PEF. There were no significant differences between drugs for any end points except EOS. CONCLUSIONS: Montelukast and salmeterol exhibited significant improvements in asthma control when given as second-line therapy. Montelukast also produced significant effects on AMP challenge and EOS suggesting anti-inflammatory activity.
Assuntos
Acetatos/uso terapêutico , Albuterol/análogos & derivados , Albuterol/uso terapêutico , Antiasmáticos/administração & dosagem , Anti-Inflamatórios/administração & dosagem , Asma/tratamento farmacológico , Broncodilatadores/uso terapêutico , Antagonistas de Leucotrienos/administração & dosagem , Quinolinas/uso terapêutico , Monofosfato de Adenosina , Administração por Inalação , Administração Tópica , Agonistas Adrenérgicos beta/administração & dosagem , Adulto , Asma/metabolismo , Asma/fisiopatologia , Testes Respiratórios , Testes de Provocação Brônquica , Estudos Cross-Over , Ciclopropanos , Eosinófilos , Feminino , Glucocorticoides , Humanos , Contagem de Leucócitos , Masculino , Óxido Nítrico/análise , Pico do Fluxo Expiratório , Mecânica Respiratória , Xinafoato de Salmeterol , Método Simples-Cego , Esteroides , SulfetosRESUMO
OBJECTIVES: High-dose nebulised fluticasone propionate (FP) has been advocated for use in patients with severe persistent asthma. As there is complete first-pass inactivation of FP for the swallowed fraction, systemic absorption is due solely to its lung bioavailability. We wished to compare the relative lung delivery of FP, using adrenal suppression as a surrogate for the respirable dose, when administered via large volume spacer (FP-spacer) or nebuliser (FP-neb) in healthy adults. METHODS: Fourteen healthy subjects, mean (SEM) age 29.4 +/- 2.6 years, were studied in a placebo-controlled, randomised study with three-way crossover design. Single nominal 2-mg doses of the following were given at 1700 hours in randomised sequence: a. FP-spacer: fluticasone pressurised metered dose inhaler (as Flixotide 250 microg ex-valve per actuation), eight puffs via a primed Volumatic 750-ml spacer. b. FP-neb: (as Flixotide Nebule 2 mg/2 ml) via Pari LC Plus nebuliser. c. Placebo nebuliser. Following each dose, measurements were made of corrected 0800-hours urinary cortisol/creatinine ratio (the primary outcome variable) and 0800-hours plasma cortisol. RESULTS: Significant (P<0.05) suppression of both endpoints occurred only with FP-spacer, FP-neb being statistically no different from placebo. Geometric mean fold differences between FP-spacer and placebo were 9.8-fold [95% confidence interval (CI) 3.4, 28.8] for urinary cortisol/creatinine and 4.1-fold (95% CI 2.2, 7.5) for plasma cortisol. Comparing FP-spacer with FP-neb, these differences were 6.8-fold (95% CI 2.3, 20.0) for urinary cortisol/creatinine and 3.3-fold (95% CI 1.8, 6.0) for plasma cortisol. CONCLUSION: For a 2-mg labelled nominal dose of fluticasone, the spacer produced about a sevenfold higher relative lung dose than the nebuliser. This suggests that a very little of the labelled nebulised dose is respirable. Other factors such as patient preference, cost and compliance will determine the inhaler device that is chosen.
Assuntos
Androstadienos/administração & dosagem , Antiasmáticos/administração & dosagem , Pulmão/efeitos dos fármacos , Administração por Inalação , Adulto , Androstadienos/farmacocinética , Antiasmáticos/farmacocinética , Disponibilidade Biológica , Biomarcadores/sangue , Biomarcadores/urina , Creatinina/urina , Estudos Cross-Over , Feminino , Fluticasona , Humanos , Hidrocortisona/sangue , Hidrocortisona/urina , Masculino , Nebulizadores e VaporizadoresRESUMO
Leukotriene receptor antagonists (LTRA) are a new class of drugs for asthma treatment, available in tablet form. Their unique mechanism of action results in a combination of both bronchodilator and anti-inflammatory effects. While their optimal place in asthma management is still under review, LTRA represent an important advance in asthma pharmacotherapy.
Assuntos
Acetatos/uso terapêutico , Antiasmáticos/uso terapêutico , Asma/tratamento farmacológico , Antagonistas de Leucotrienos , Quinolinas/uso terapêutico , Compostos de Tosil/uso terapêutico , Asma Induzida por Exercício/tratamento farmacológico , Doença Crônica , Ciclopropanos , Humanos , Indóis , Fenilcarbamatos , Sulfetos , SulfonamidasRESUMO
To compare the antiasthmatic efficacy of inflammatory mediator blockade versus topical corticosteroid therapy in patients with seasonal allergic rhinitis (SAR) and asthma, 14 patients were enrolled into a single-blind, double-dummy, placebo-controlled crossover study comparing 2 wk therapy of (1) 400 microgram orally inhaled budesonide plus 200 microgram intranasal budesonide (BUD) or (2) 10 mg oral montelukast plus 10 mg oral cetirizine (ML + CZ). Before each treatment period, patients received 7 to 10 d placebo washout. All treatments were given once daily in the morning. Throughout the study, patients recorded the following domiciliary measures: peak expiratory flow (PEF), rescue inhaler requirement, asthma symptoms, and daily activity score. Laboratory measurements were made at trough of adenosine monophosphate (AMP) bronchial challenge and exhaled nitric oxide (NO). Compared with pooled placebo (PL), there were significant (p < 0.05) improvements in all domiciliary measures with both treatments (mean PEF [L/min] PL: 463; BUD: 478; ML + CZ: 483). For geometric mean AMP PC(20) (mg/ml), there was an improvement (p < 0.05), compared with PL (47), for ML + CZ (133) but not for BUD (51); whereas for NO (ppb) there was significant suppression with BUD (7.6) but not ML + CZ (11.5) compared with PL (13.6). In conclusion, both combined mediator blockade and combined topical corticosteroids are equally effective antiasthma therapy in patients with asthma and SAR.
Assuntos
Acetatos/administração & dosagem , Antiasmáticos/administração & dosagem , Asma/tratamento farmacológico , Budesonida/administração & dosagem , Cetirizina/administração & dosagem , Mediadores da Inflamação/antagonistas & inibidores , Antagonistas de Leucotrienos/administração & dosagem , Quinolinas/administração & dosagem , Rinite Alérgica Sazonal/tratamento farmacológico , Acetatos/efeitos adversos , Administração por Inalação , Administração Oral , Antiasmáticos/efeitos adversos , Testes de Provocação Brônquica , Budesonida/efeitos adversos , Cetirizina/efeitos adversos , Estudos Cross-Over , Ciclopropanos , Método Duplo-Cego , Quimioterapia Combinada , Volume Expiratório Forçado/efeitos dos fármacos , Humanos , Antagonistas de Leucotrienos/efeitos adversos , Quinolinas/efeitos adversos , SulfetosRESUMO
Bronchial hyperresponsiveness (BHR) is a key feature of asthma and may be measured by direct methacholine challenge or indirect adenosine monophosphate (AMP) challenge. We performed a retrospective analysis of our database (n = 487) of patients with asthma with the aim first, to compare methacholine and AMP challenge as screening tools, and second, to identify any relationships between BHR and disease severity markers or beta(2)-adrenoceptor genotype. Of these subjects, 258 had a methacholine challenge, 259 an AMP challenge and 185 both. Of subjects having both, 140 (76%) were methacholine responsive with PD(20) < 500 microgram (PC(20) < 5 mg/ml) and 92 (50%) were AMP responsive with PC(20) < 200 mg/ ml. For those who were AMP unresponsive 57% were methacholine responsive, whereas for the methacholine nonresponders 11% were AMP responsive. Methacholine (but not AMP)-responsive patients had a significantly (p < 0.05) lower % predicted FEV(1) and FEF(25-75) and higher inhaled corticosteroid dose than unresponsive patients. Finally, subjects with a glycine allele at codon 16 had significantly (p < 0.05) increased BHR to methacholine but not AMP. Our results suggest that methacholine is a more appropriate screening tool for BHR than AMP as it was more sensitive in our population and was also related to asthma severity. In addition, we have demonstrated an association between the glycine allele (codon 16) and increased BHR to methacholine.
Assuntos
Monofosfato de Adenosina , Asma/diagnóstico , Hiper-Reatividade Brônquica/diagnóstico , Testes de Provocação Brônquica , Genótipo , Programas de Rastreamento , Cloreto de Metacolina , Receptores Adrenérgicos beta 2/genética , Adulto , Asma/genética , Hiper-Reatividade Brônquica/genética , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Polimorfismo Genético/genética , Valor Preditivo dos Testes , Estudos RetrospectivosRESUMO
PURPOSE: In the United Kingdom, about 40% of patients with asthma are homozygous for the glycine-16 beta(2)-adrenoceptor polymorphism, which predisposes them to agonist-induced down-regulation and desensitization of the beta(2)-adrenoceptor. We assessed the effects of adding treatment with either a long-acting beta(2)-agonist (inhaled formoterol, 12 microg twice daily) or a leukotriene receptor antagonist (oral zafirlukast, 20 mg twice daily) to inhaled corticosteroid therapy in patients with this genotype. SUBJECTS AND METHODS: We enrolled 24 patients with mild to moderate asthma who were being treated with inhaled corticosteroids. Patients were randomly assigned to receive one of three treatments (placebo, zafirlukast, or formoterol in addition to inhaled corticosteroids) for 1 week each in a crossover fashion, separated by a 1-week placebo run-in and washout period. Measurements of bronchoprotection (measured as the provocative dose of methacholine that produced a 20% decline in forced expiratory volume in 1 second [FEV(1)]), exhaled nitric oxide (a surrogate marker of airway inflammation), and symptoms were made before each treatment and 12 hours after the last dose of each treatment. RESULTS: Both formoterol and zafirlukast were equally effective in maintaining asthma control compared with placebo: the geometric mean-fold difference in the methacholine provocative dose was 1.5-fold (95% confidence interval [CI]: 1.1- to 2.2-fold) for zafirlukast and 1.9-fold (95% CI: 1.2- to 2.9-fold) for formoterol. As compared with placebo, zafirlukast caused a significant suppression in exhaled nitric oxide (1.7-fold difference in geometric mean values, 95% CI: 1.1- to 2.6-fold) but formoterol did not (1.2-fold difference, 95% CI: 0.8- to 1.9-fold). Diary cards showed significant (P <0.05) improvements in the peak flow with formoterol (morning and evening) and zafirlukast (evening) as compared with placebo. CONCLUSIONS: Formoterol and zafirlukast maintained asthma control in patients who might be genetically predisposed to fare worse with long-acting beta(2)-agonists. The reduction in exhaled nitric oxide with zafirlukast suggests that it may have anti-inflammatory effects in addition to those seen with inhaled corticosteroids.
Assuntos
Agonistas Adrenérgicos beta/uso terapêutico , Antiasmáticos/uso terapêutico , Asma/tratamento farmacológico , Antagonistas de Leucotrienos/uso terapêutico , Receptores Adrenérgicos beta 2/genética , Administração por Inalação , Agonistas Adrenérgicos beta/administração & dosagem , Adulto , Idoso , Antiasmáticos/administração & dosagem , Asma/genética , Beclometasona/administração & dosagem , Beclometasona/uso terapêutico , Hiper-Reatividade Brônquica/tratamento farmacológico , Broncodilatadores/administração & dosagem , Broncodilatadores/uso terapêutico , Intervalos de Confiança , Estudos Cross-Over , Etanolaminas/administração & dosagem , Etanolaminas/uso terapêutico , Feminino , Volume Expiratório Forçado/efeitos dos fármacos , Fumarato de Formoterol , Genótipo , Glucocorticoides/administração & dosagem , Glucocorticoides/uso terapêutico , Glicina/genética , Homozigoto , Humanos , Indóis , Antagonistas de Leucotrienos/administração & dosagem , Masculino , Pessoa de Meia-Idade , Óxido Nítrico/metabolismo , Fenilcarbamatos , Placebos , Polimorfismo Genético/genética , Sulfonamidas , Compostos de Tosil/administração & dosagem , Compostos de Tosil/uso terapêuticoRESUMO
BACKGROUND: Although there is a recognized association between upper and lower allergic airways disease, it is unknown how seasonal allergic rhinitis (SAR) therapy will effect sensitive markers of airway function in patients with no history of asthma. OBJECTIVE: To prospectively evaluate subjective and objective markers of treatment response in 26 patients with SAR who have been screened to exclude a diagnosis of asthma. METHODS: The patients' usual treatment, with antihistamine alone (n = 13) or in combination with intranasal corticosteroid (n = 13), was withheld for 1 week to achieve a baseline and then resumed. Measurements were made after baseline and after 2 and 4 weeks of treatment for nasal peak inspiratory flow rate (nPIFR); airways resistance (Raw) and specific conductance (sGaw); and nasal nitric oxide (NO). Patients reported their symptom (nasal, throat and eye) scores, daily activity scores, and ocular sodium cromoglycate usage over the preceding 24 hours. RESULTS: Compared with baseline, there were significant (P < .05) improvements with nPIFR, symptom scores and cromoglycate usage at 2 and 4 weeks of treatment. There was no significant suppression for NO at 2 or 4 weeks. There was a significant correlation between nPIFR and nasal symptoms (r = -0.52, P < .001). After 4 weeks of treatment there were significant (P < .05) improvements in sGaw (143.3% predicted) and Raw (91.6% predicted) compared with baseline (sGaw: 111.8%, Raw: 104.2% predicted). CONCLUSION: Treatment of SAR improves upper and lower airway parameters but not NO. Nasal PIFR correlates significantly with nasal symptoms.